INVASIVE CARCINOMA OF THE BREAST

Specimen: [left breast; right breast; not specified; cannot be determined]

Procedure: [wide-local excision; lumpectomy; skin-sparing mastectomy; nipple-sparing mastectomy; simple mastectomy; modified radical mastectomy; not specified; cannot be determined]

Sentinel Lymph Node Sampling: [performed; not performed; not specified; cannot be determined]

Non-sentinel Lymph Node Sampling: [performed; not performed; not specified; cannot be determined]

Neoadjuvant Therapy: [performed; not performed; not specified; cannot be determined]

Tumor Laterality: [left breast, right breast, not specified; cannot be determined]

Tumor Focality: [unifocal; multifocal; cannot be determined]

Tumor Site: [upper outer quadrant; lower inner quadrant; upper inner quadrant; lower inner quadrant; central; nipple; subareolar; other (specify); not specified; cannot be determined]

Tumor Size: [microinvasion (less than or equal to 0.1 cm); greatest dimension of invasive focus; no residual invasive carcinoma; cannot be determined]

Histologic Type: [designate the type of invasive carcinoma using the most recent WHO Classification]

Histologic Grade: [provide grade as defined by modified Bloom-Richardson criteria]

Biomarker Status: (if performed on a different specimen, give accession number)
  • ER: [POSITIVE (give percentage of tumor cells positive and staining intensity if known); NEGATIVE (< 1%); PENDING; UNKNOWN]
  • PR: [POSITIVE (give percentage of tumor cells positive and staining intensity if known); NEGATIVE (< 1%); PENDING; UNKNOWN]
  • HER2 IHC: [POSITIVE (3+); EQUIVOCAL (2+); NEGATIVE (state if 0 or 1+); PENDING; UNKNOWN]
  • HER2 FISH: [state if FISH was POSITIVE, NEGATIVE, or EQUIVOCAAL and provide HER2:CEP17 ratio and average number of HER2 signals per cell]

Block for oncotype testing: _______
Extensive Intraductal Component (EIC): [present; not identified; cannot be determined]

Tumor Extension: [designate if there is skin, nipple, or chest wall involvement]

Lymph-Vascular Invasion: [present; absent; not identified; cannot be determined]

Microcalcifications: [present in DCIS; present in invasive carcinoma; present in benign ducts and/or lobules; not identified; cannot be determined]

Treatment Effect: [no definite response to presurgical therapy in the invasive carcinoma; probably or definite response to presurgical therapy in the invasive carcinoma; no residual invasive carcinoma is present in the breast after presurgical therapy; no known presurgical therapy; cannot be determined]

Surgical Margins:
- Invasive carcinoma: [negative (provide closest margin and distance to margin); positive (state specific margin and linear extent of positive margin); cannot be determined]
- DCIS: [negative by ≥ 0.2 cm; positive (state specific margin and linear extent of positive margin); cannot be determined]

Sentinel Lymph Node Status: [# positive lymph nodes / total # of lymph nodes]
- [If positive, give largest size of metastatic focus in cm]
- [If positive, state if there is microscopic or gross extranodal extension]

Total Lymph Node Status: [# positive lymph nodes / total # of lymph nodes]
- [If positive, give largest size of metastatic focus in cm]
- [If positive, state whether the metastasis is located in the highest axillary lymph node]
- [If positive, state if there is microscopic or gross extranodal extension]

With available surgical materials AJCC: [pT_ N_] (8th edition)